Cryolife Inc (NYSE:CRY) has been assigned an average rating of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $23.63.
A number of equities analysts recently issued reports on the company. Canaccord Genuity reissued a “buy” rating and issued a $25.00 price objective on shares of Cryolife in a report on Monday, October 9th. Lake Street Capital increased their price objective on Cryolife to $26.00 and gave the stock a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research lowered Cryolife from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. TheStreet lowered Cryolife from a “b” rating to a “c+” rating in a report on Monday, October 30th. Finally, Northland Securities reissued a “buy” rating and issued a $23.50 price objective on shares of Cryolife in a report on Monday, November 13th.
In other Cryolife news, CAO Amy Horton sold 4,000 shares of the stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $19.00, for a total transaction of $76,000.00. Following the completion of the transaction, the chief accounting officer now directly owns 98,705 shares of the company’s stock, valued at approximately $1,875,395. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP David C. Gale sold 20,000 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $19.63, for a total value of $392,600.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 59,190 shares of company stock valued at $1,138,240. 6.00% of the stock is currently owned by corporate insiders.
Cryolife (NYSE:CRY) opened at $18.20 on Friday. Cryolife has a fifty-two week low of $14.02 and a fifty-two week high of $24.00. The stock has a market capitalization of $610.60, a P/E ratio of 65.00 and a beta of 0.82. The company has a debt-to-equity ratio of 0.29, a current ratio of 5.96 and a quick ratio of 4.90.
Cryolife (NYSE:CRY) last issued its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.08. Cryolife had a return on equity of 6.43% and a net margin of 5.28%. The business had revenue of $44.00 million during the quarter, compared to analyst estimates of $44.60 million. During the same period in the prior year, the company posted $0.13 EPS. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. analysts anticipate that Cryolife will post 0.28 earnings per share for the current fiscal year.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.